"Prevention is so much better than healing because it saves the labour of being sick." Thomas Adams, 1618"Prevention is so much better than healing because it saves the labour of being sick."
Thomas Adams, 1618

OncoTrack kicks off search for novel genomic cancer diagnostics

OncoTrack kicks off search for novel genomic cancer diagnostics

March 9, 2011

OncoTrack, an international consortium of over 60 scientists, managed by Bayer HealthCare Pharmaceuticals and the Max Planck Institute for Molecular Genetics, launches one of Europe’s largest collaborative academic-industry research projects to develop and assess novel approaches for identification of new markers for colon cancer. The unique five-year project, Methods for systematic next generation oncology biomarker development, brings together top scientists from European academic institutions with a wide range of expertise, and partners them with pharmaceutical companies. iPRI is one of the involved research centres.

The essential objective of OncoTrack is to establish new methods for systematic next generation oncology biomarker development. Detailed molecular characterization of high quality tumor tissue will provide critical information to support our fundamental understanding of cancer and the influence of heterogeneity on response to colon cancer therapy. The project intends to generate high-quality genomic and epigenetic sequence data from clinically well-defined tumors and their metastases, and will compare these to the germline genome of the patients. These data will be complemented by a detailed molecular characterization of the tumors. In parallel, the consortium will establish and characterize a novel series of xenograft tumor models and cell lines derived from the same set of tumors which will support research on tumor biology and also the early stages of biomarker qualification. The combined data from all phases of the project will allow OncoTrack to address fundamental questions regarding the relationships between tumor genotype and phenotype, thus providing the starting point for discovery and selection of suitable candidates for development as biomarkers of colon cancer.

Prof. Hans Lehrach, Leader of the Managing Entity from the Max Planck Institute for Molecular Genetics comments: ‘We welcome the unique opportunity afforded by this IMI initiative. The broad support from Europes’ top pharma companies combined with the expertise within our Institute and our partners, will enable us to achieve the leverage necessary to tackle this complex project. Additionally the access to the scientists & commercial research facilities afforded by members of the OncoTrack Consortium will allow us to adopt avenues of discovery previously out of reach for academic research institutes. I look forward to our collaboration and feel that this initiative will both strengthen European academic research and provide our industry partners with important new tools applicable to clinical development programmes. Most importantly, our research will yield tangible benefits to patients in the therapy and management of their disease’.

The project Methods for systematic next generation oncology biomarker development, is partnered with a selected group of major global pharmaceutical companies, composed of AstraZeneca, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Janssen Pharmaceutica, Merck, Pfizer and Roche Diagnostics, whose in-kind contributions to the project are matched by funding from the IMI Joint Undertaking, resulting in a total budget of €25.8 mio.

The academic partners contribute essential skills & knowledge crucial toward the success of this enterprise. Those involved include: the Max Planck Institute for Molecular Genetics (Germany), Uppsala Universitet (Sweden), University College London (United Kingdom), Université Paris-Sud (France), Charité Universitätsmedizin Berlin (Germany), the Medizinische Universität Graz (Austria) and the Technische Universität Dresden (Germany). Aiding this ground-breaking project are three further pharmaceutical small and medium-sized enterprises (SME), International Prevention Research Institute (France), Experimental Pharmacology and Oncology and Alacris Theranostics (both in Germany), who will contribute to the success of OncoTrack, while the SME GABO:mi (Germany) will have the complex task of managing the multi-national project.

Leave a Comment





Latest News

Latest Posts

Quick Contact

Please enter your name.
Please enter a message.
Positive SSL